Entropy files new US patent for IBS program
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This patent complements an existing Australian patent and aims to enhance the company's intellectual property position in the gut-brain disorder market. CEO Jason Carroll emphasized the importance of this filing in strengthening the company's position in the emerging field of psychedelic therapies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- TRP 8802 delivers 75% breakthrough response in IBS
- TRP-8803 delivers repeatable, high-intensity effect
- FY25 R&D Tax Incentive received
- Cohort 1 enrolment achieved for TRP-8803 BED Trial
- Appendix 4D and Half Year Report for period 31 Dec 2025
Later from Entropy Neurodynamics
- Entropy completes Cohort 1 dosing in BED trial
- DSMB Clears TRP 8803 to Advance to Cohort 2
- 100% Clinical improvement, 50% Remission in BED study
- South Africa Grants ENP Broad Fibromyalgia Patent to 2043
- 72-Patient Trial Fast-Tracks TRP-8803 Commercialisation
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics